We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Immunotherapy company Aduro Biotech has announced it has initiated its Phase 1b study of its ADU-214 drug in combination with nivolumab to treat advanced metastatic non-small cell lung cancer.